Stanford CAP Profile
Oliver Dorigo, MD, PhD, is Director and Associate Professor in the Division of Gynecologic Oncology at Stanford. His clinical responsibilities include the Direction of the Gynecologic Oncology Clinical Care Program at the Stanford Women's Cancer Center, and the conduction of clinical trials in Gynecologic Oncology at Stanford. He is the Director of the Mary Lake Polan Gynecologic Oncology Research Laboratory which is focused on the development of novel therapies for ovarian cancer.
Dr. Dorigo received his medical degree from the University of Heidelberg Medical School in Germany, followed by residency training in Obstetrics and Gynecology at the University of Munich, Germany, He joined the Cancer Gene Therapy at the Sidney Kimmel Cancer Center in San Diego, CA, and participated in early clinical trials using gene therapy for cancer disease. Dr. Dorigo subsequently moved to the UCLA David Geffen School of Medicine, Los Angeles, CA, and completed his residency in Obstetrics and Gynecology. He then joined a PhD program at UCLA, and earned his degree in Molecular Biology while working on the development of a new gene transfer system. His research has been published in various scientific journals, including Journal of Virology, Proceedings of the National Academy of Sciences, Journal of Immunology, and Cancer Gene Therapy.
Following his PhD basic science training, Dr. Dorigo completed a clinical fellowship in Gynecologic Oncology at UCLA /Cedars Sinai Medical Center. He subsequently joined the Division of Gynecologic Oncology in the UCLA Department of Obstetrics and Gynecology. Dr. Dorigo joined Stanford University as the Director of Gynecologic Oncology, as of April 2013.
His clinical focus is the treatment of patients with gynecologic cancers, including ovarian, cervical, endometrial, vaginal and vulva cancer. In his surgical practice, Dr. Dorigo is emphasizing the use of minimal invasive technologies in particular laparoscopic and robotic surgery. In addition to his clinical practice, Dr. Dorigo is committed to the development of innovative new therapies for patient with gynecologic malignancies. These efforts are focused both on the continuous expansion of the clinical trials program in Gynecologic Oncology and the Stanford Cancer Center, as well as the preclinical development of novel therapies in the laboratory.